Role for the nuclear factor κB pathway in transforming growth factor-β1 production in idiopathic myelofibrosis: Possible relationship with FK506 binding protein 51 overexpression

Cancer Research

Volumn 65, Issue 8, 2005, Pages 3281-3289

  Komura, Emiko ^a   Tonetti, Carole ^b   Penard Lacronique, Virginie ^c   Chagraoui, Hédia ^a   Lacout, Catherine ^a   LeCouédic, Jean Pierre ^a   Rameau, Philippe ^a   Debili, Najet ^a   Vainchenker, William ^a   Giraudier, Stéphane ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FK 506 BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ARTICLE; HUMAN; HUMAN CELL; MEGAKARYOCYTE; MYELOID METAPLASIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 20244377844     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2339     Document Type: Article

References (39)

1. Castro-Malaspina H. Role of ineffective megakaryopoiesis and megakaryocyte components. Prog Clin Biol Res 1984;154:427-54.
2. Castro-Malaspina H, Moore MA. Pathophysiological mechanisms operating in the development of myelofibrosis: role of megakaryocytes. Nouv Rev Fr Hematol 1982;24:221-6.
3. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis. Ann Hematol 2001;80:160-5.
4. Rameshwar P, Denny TN, Stein D, Gascon P. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-I and TGFβ. J Immunol 1994;153:2819-30.
5. Rameshwar P, Narayanan R, Qian J, Denny TN, Colon C, Gascon P. NF-κB as a central mediator in the induction of TGF-β in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol 2000;165:2271-7.
6. Yan X-Q, Lacey D, Hill D, et al. A model of myelofibrosis and osteosclerosis in mice induced by over-expressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood 1996;88:402-9.
7. Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 1997;90:4369-83.
8. low mice). Blood 2002;100:1123-32.
9. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-β1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002;100:3495-503.
10. + hematopoietic progenitors from patients with idiopathic myelofibrosis. Blood 2003;101:5087-8.
11. Giraudier S, Chagraoui H, Komura E, et al. Over-expression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. Blood 2002;100:2932-40.
12. Komura E, Chagraoui H, de Mas VM, et al. Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 over-expression. Exp Hematol 2003;31:622-30.
13. Bouwmeester T, Bauch A, Ruffer H, et al. A physical and functional map of the human TNF-α/NF-κB signal transduction pathway. Nat Cell Biol 2004;6:97-105.
14. Debili N, Wendling F, Katz A, et al. The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood 1995;86:2516-25.
15. Wang CY, Mayo MW, Baaldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996;274:784.
16. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of κBα proteolysis by site-specific, signal-induced phosphorylation. Science 1995;267:1485-8.
17. Schmitz ML, Baeuerle PA. Multi-step activation of NF-κB/Rel transcription factors. Immunobiology 1995;193:116-27.
18. Shuai K, Halpem J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996;13:247-54.
19. Naumann M, Scheidereit C. Activation of NF-κB in vivo is regulated by multiple phosphorylations. EMBO J 1994;13:4597-607.
20. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionary conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
21. BCR-ABL activates p65 NF-κB). Oncogene 1997;15:2267-75.
22. Le Bousse-Kerdiles MC, Martyre MC. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis an myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol 1999;78:437-44.
23. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994;331:1286-92.
24. Rameshwar P, Chang VT, Thacker UF, Gascon P. Systemic transforming growth factor-β in patients with bone marrow fibrosis: pathophysiological implications. Am J Hematol 1998;59:133-42.
25. Hatzfeld J, Li ML, Brown EL, et al. Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor β1 or Rb oligonucleotides. J Exp Med 1991;174:925-9.
26. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signaling cascades. Nature 2001;412:641-7.
27. Santos SC, Monni R, Bouchaert I, et al. Involvement of the NF-κB pathway in the transforming properties of the TEL-Jak2 leukemogenic fusion protein. FEBS Lett 2001;497:148-52.
28. Pons S, Torres-Aleman I. Insulin-like growth factor-I stimulates dephosphorylation of IκB through the serine phosphatase calcineurin (protein phosphatase 2B). J Biol Chem 2000;275:38620-5.
29. Biswas G, Anandatheerthavarada HK, Zaidi M, Avadhani NG. Mitochondria to nucleus stress signaling: a distinctive mechanism of NFκB/Rel activation through calcineurin-mediated inactivation of IκBβ. J Cell Biol 2003;161:507-19.
30. Fowlis DJ, Flanders KC, Duffie E, Balmain A, Akhurst RJ. Discordant transforming growth factor β1 RNA and protein localization during chemical carcinogenesis of the skin. Cell Growth Differ 1992;3:81-91.
31. Fraser D, Wakefield L, Phillips A. Independent regulation of Transforming growth factor-β1 transcription and translation by glucose and platelet-derived growth factor. Am J Pathol 2002;161:1039-49.
32. Sonenberg N. mRNA translation: influence of the 5′ and 3′ untranslated regions. Curr Opin Genet Dev 1994;4:310-5.
33. Kim SJ, Park K, Koellers D, et al. Post-transcriptional regulation of the human transforming growth factor-b1 gene. J Biol Chem 1992;267:13702-7.
34. Phillips AO, Topley N, Morrisey K, Williams JD, Steadman R. Basic fibroblast growth factor stimulates the release of pre-formed TGF-β1 from human proximal tubular cells in the absence of de-novo gene transcription or mRNA translation. Lab Invest 1997;76:591-600.
35. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
36. Dupriez B, Demory JL, Lai JL, Fenaux P, Bauters F. Prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 1989;73:136-7.
37. Blanchet B, Hulin A, Duvoux C, Astier A. Determination of serine/threonine protein phosphatase type 2B PP2B in lymphocytes by HPLC. Anal Biochem 2003;312:1-6.
38. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14.
39. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996;88:1013-8.